Riskpilot← Back to searchSign inGet full accessPharmaval AB
ABActiveOrg 5566793039Industrivägen 18Rental and operating of own or leased real estate · NACE 6820Est. 20050 employees
Revenue 2025
SEK 8,8M
+51% vs 2024
EBITDA margin
94.3%
+59% vs 2024
Equity ratio
44.5%
Financial strength
Net profit 2025
SEK 1,9M
-45% vs 2024
| Revenue | SEK 8,8M | +51% |
| EBITDA | SEK 8,3M | +59% |
| Net profit | SEK 1,9M | -45% |
| Total assets | SEK 36M | -4% |
| Equity | SEK 16M | +14% |
| Employees | 0 | — |
Legal name
Pharmaval AB
Org number
5566793039
Legal form
Aktiebolag
NACE code
6820 · Rental and operating of own or leased real estate
Founded
15 april 2005
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva svetsningsarbeten samt äga och förvalta fastigheter, produktion och försäljning av energi samt därmed förenlig verksamhet.
Address
Industrivägen 18
Email
invoice@nordholms.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 2 589 | 2 664 | 2 786 | 2 784 | 2 980 | 4 759 | 5 853 | 8 815 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | 2 131 | 2 255 | 2 370 | 2 421 | 2 507 | 2 539 | 2 092 | 4 273 | 5 241 | 8 309 |
| Depreciation & amort. | −515 | −515 | −506 | −667 | −621 | −610 | −621 | −642 | −829 | −1 032 |
| EBIT | 1 616 | 1 740 | 1 864 | 1 754 | 1 886 | 1 929 | 1 471 | 3 631 | 4 412 | 7 277 |
| Net financials | −365 | −281 | −183 | −181 | −178 | −150 | −97 | −332 | −716 | −523 |
| Profit before tax | 1 053 | 1 349 | 1 380 | 1 380 | 1 533 | 1 577 | 1 123 | 548 | 4 586 | 2 247 |
| Tax | −131 | −378 | −304 | −282 | −331 | −337 | −234 | −123 | −1 110 | −322 |
| Net profit | 922 | 971 | 1 076 | 1 098 | 1 202 | 1 240 | 889 | 425 | 3 476 | 1 924 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 22 570 | 21 215 | 21 685 | 20 538 | 20 495 | 20 263 | 19 391 | 27 660 | 37 427 | 36 003 |
| Equity | 3 715 | 4 685 | 5 761 | 6 860 | 8 062 | 9 303 | 10 192 | 10 617 | 14 093 | 16 018 |
| Long-term debt | 16 253 | 13 638 | 12 623 | 11 458 | 9 943 | 7 970 | 6 129 | 9 928 | 19 550 | 10 950 |
| Short-term debt | 1 899 | 1 897 | 1 902 | 570 | 588 | 809 | 562 | 4 782 | 2 236 | 8 148 |
| Total debt | 18 152 | 15 535 | 14 525 | 12 028 | 10 531 | 8 779 | 6 691 | 14 710 | 21 786 | 19 098 |
EBITDA margin
94.3%
This company
15.8%
Market median
+497% vs market
20162025
Equity ratio
44.5%
This company
38.2%
Market median
+16% vs market
20162025
Return on equity
12.0%
This company
18.4%
Market median
+35% vs market
20162025
Net profit margin
21.8%
This company
8.1%
Market median
+169% vs market
20162025
Asset turnover
0.24×
This company
1.12×
Market median
-79% vs market
20162025
Debt / equity
1.25×
This company
0.62×
Market median
-102% vs market
20162025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-09-01 – 2020-08-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-09-01 – 2019-08-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-09-01 – 2018-08-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-09-01 – 2017-08-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-09-01 – 2016-08-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
IB | Audit | 2022 | — | — |
RD Auditor Substitute | Auditor Substitute | 2024 | — | — |
SA Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
AS Audit | Audit | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Nordholms Construction AB | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Nordholms Construction AB
Pharmaval AB Board members of Pharmaval AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ivar Bjarne Fredriksson | Audit | 0 companies |
| Rolf Daniel Linsten | Auditor Substitute | 0 companies |
| Sofia Antoinette Kristina Hygrell | Chief Executive Officer | 0 companies |
| Anna Sofia Ingman | Audit | 0 companies |
| Jan Anders Hygrell | Board of Directors | 0 companies |